nodes	percent_of_prediction	percent_of_DWPC	metapath
Aminosalicylic Acid—PTGS2—skeletal joint—systemic scleroderma	0.0185	0.0805	CbGeAlD
Aminosalicylic Acid—MPO—artery—systemic scleroderma	0.0171	0.0743	CbGeAlD
Aminosalicylic Acid—MPO—endothelium—systemic scleroderma	0.0144	0.0628	CbGeAlD
Aminosalicylic Acid—CHUK—connective tissue—systemic scleroderma	0.0143	0.0623	CbGeAlD
Aminosalicylic Acid—MPO—blood vessel—systemic scleroderma	0.0133	0.0579	CbGeAlD
Aminosalicylic Acid—CHUK—skin of body—systemic scleroderma	0.0129	0.0562	CbGeAlD
Aminosalicylic Acid—CHUK—digestive system—systemic scleroderma	0.0103	0.045	CbGeAlD
Aminosalicylic Acid—CHUK—lung—systemic scleroderma	0.00863	0.0376	CbGeAlD
Aminosalicylic Acid—PTGS1—artery—systemic scleroderma	0.0081	0.0353	CbGeAlD
Aminosalicylic Acid—ALOX5—connective tissue—systemic scleroderma	0.00806	0.0351	CbGeAlD
Aminosalicylic Acid—PTGS2—artery—systemic scleroderma	0.00774	0.0337	CbGeAlD
Aminosalicylic Acid—CHUK—Rac1/Pak1/p38/MMP-2 pathway—TNIP1—systemic scleroderma	0.00769	0.0344	CbGpPWpGaD
Aminosalicylic Acid—ALOX5—smooth muscle tissue—systemic scleroderma	0.00737	0.0321	CbGeAlD
Aminosalicylic Acid—PTGS2—Fluocinonide—Mometasone—systemic scleroderma	0.00725	0.624	CbGdCrCtD
Aminosalicylic Acid—MPO—IL23-mediated signaling events—STAT4—systemic scleroderma	0.00691	0.0309	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—endothelium—systemic scleroderma	0.00684	0.0298	CbGeAlD
Aminosalicylic Acid—MPO—connective tissue—systemic scleroderma	0.00682	0.0297	CbGeAlD
Aminosalicylic Acid—PTGS2—endothelium—systemic scleroderma	0.00654	0.0285	CbGeAlD
Aminosalicylic Acid—PTGS1—blood vessel—systemic scleroderma	0.00631	0.0275	CbGeAlD
Aminosalicylic Acid—MPO—skin of body—systemic scleroderma	0.00616	0.0268	CbGeAlD
Aminosalicylic Acid—PTGS2—blood vessel—systemic scleroderma	0.00603	0.0263	CbGeAlD
Aminosalicylic Acid—MPO—Folate Metabolism—CSF1—systemic scleroderma	0.00596	0.0267	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Canonical NF-kappaB pathway—TNFAIP3—systemic scleroderma	0.00589	0.0264	CbGpPWpGaD
Aminosalicylic Acid—ALOX5—digestive system—systemic scleroderma	0.00582	0.0253	CbGeAlD
Aminosalicylic Acid—CHUK—Validated transcriptional targets of TAp63 isoforms—GDF15—systemic scleroderma	0.00539	0.0241	CbGpPWpGaD
Aminosalicylic Acid—MPO—digestive system—systemic scleroderma	0.00492	0.0214	CbGeAlD
Aminosalicylic Acid—ALOX5—lung—systemic scleroderma	0.00486	0.0212	CbGeAlD
Aminosalicylic Acid—CHUK—HIV-1 Nef: Negative effector of Fas and TNF-alpha—CD247—systemic scleroderma	0.00472	0.0211	CbGpPWpGaD
Aminosalicylic Acid—CHUK—NOD1/2 Signaling Pathway—TNFAIP3—systemic scleroderma	0.00464	0.0208	CbGpPWpGaD
Aminosalicylic Acid—MPO—C-MYB transcription factor network—COL1A2—systemic scleroderma	0.00448	0.0201	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Fluticasone Propionate—Mometasone—systemic scleroderma	0.00438	0.376	CbGdCrCtD
Aminosalicylic Acid—MPO—lung—systemic scleroderma	0.00411	0.0179	CbGeAlD
Aminosalicylic Acid—CHUK—Downstream TCR signaling—CD247—systemic scleroderma	0.00396	0.0177	CbGpPWpGaD
Aminosalicylic Acid—CHUK—TCR signaling in naïve CD8+ T cells—CSK—systemic scleroderma	0.00343	0.0154	CbGpPWpGaD
Aminosalicylic Acid—CHUK—TNF receptor signaling pathway —TNFAIP3—systemic scleroderma	0.00339	0.0152	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Hair Follicle Development: Induction (Part 1 of 3)—CTGF—systemic scleroderma	0.00325	0.0145	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—connective tissue—systemic scleroderma	0.00323	0.0141	CbGeAlD
Aminosalicylic Acid—CHUK—TCR signaling in naïve CD8+ T cells—CD247—systemic scleroderma	0.00323	0.0144	CbGpPWpGaD
Aminosalicylic Acid—MPO—IL23-mediated signaling events—CCL2—systemic scleroderma	0.0032	0.0143	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—TNFAIP3—systemic scleroderma	0.00317	0.0142	CbGpPWpGaD
Aminosalicylic Acid—CHUK—TCR signaling—CSK—systemic scleroderma	0.00315	0.0141	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—connective tissue—systemic scleroderma	0.00309	0.0135	CbGeAlD
Aminosalicylic Acid—CHUK—p75(NTR)-mediated signaling—RHOB—systemic scleroderma	0.00305	0.0137	CbGpPWpGaD
Aminosalicylic Acid—CHUK—TCR signaling—CD247—systemic scleroderma	0.00296	0.0133	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—smooth muscle tissue—systemic scleroderma	0.00296	0.0129	CbGeAlD
Aminosalicylic Acid—PTGS1—skin of body—systemic scleroderma	0.00292	0.0127	CbGeAlD
Aminosalicylic Acid—PTGS2—Spinal Cord Injury—AIF1—systemic scleroderma	0.0029	0.013	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Osteopontin Signaling—MMP9—systemic scleroderma	0.0029	0.013	CbGpPWpGaD
Aminosalicylic Acid—CHUK—TCR signaling in naïve CD4+ T cells—CSK—systemic scleroderma	0.00288	0.0129	CbGpPWpGaD
Aminosalicylic Acid—CHUK—BCR signaling pathway—CSK—systemic scleroderma	0.00285	0.0127	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—smooth muscle tissue—systemic scleroderma	0.00283	0.0123	CbGeAlD
Aminosalicylic Acid—Weight decreased—Captopril—systemic scleroderma	0.00281	0.00524	CcSEcCtD
Aminosalicylic Acid—Dysgeusia—Pentoxifylline—systemic scleroderma	0.00279	0.00522	CcSEcCtD
Aminosalicylic Acid—PTGS2—skin of body—systemic scleroderma	0.00279	0.0122	CbGeAlD
Aminosalicylic Acid—CHUK—IL1-mediated signaling events—IL1A—systemic scleroderma	0.00273	0.0122	CbGpPWpGaD
Aminosalicylic Acid—CHUK—TCR signaling in naïve CD4+ T cells—CD247—systemic scleroderma	0.00271	0.0121	CbGpPWpGaD
Aminosalicylic Acid—Encephalopathy—Methotrexate—systemic scleroderma	0.00271	0.00506	CcSEcCtD
Aminosalicylic Acid—Jaundice—Captopril—systemic scleroderma	0.0027	0.00504	CcSEcCtD
Aminosalicylic Acid—Anaemia—Pentoxifylline—systemic scleroderma	0.00264	0.00492	CcSEcCtD
Aminosalicylic Acid—Hypoglycaemia—Lisinopril—systemic scleroderma	0.0026	0.00487	CcSEcCtD
Aminosalicylic Acid—Agranulocytosis—Captopril—systemic scleroderma	0.00258	0.00482	CcSEcCtD
Aminosalicylic Acid—Leukopenia—Pentoxifylline—systemic scleroderma	0.00255	0.00477	CcSEcCtD
Aminosalicylic Acid—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—MMP1—systemic scleroderma	0.0025	0.0112	CbGpPWpGaD
Aminosalicylic Acid—Hepatitis—Captopril—systemic scleroderma	0.00248	0.00464	CcSEcCtD
Aminosalicylic Acid—MPO—Vitamin B12 Metabolism—CCL2—systemic scleroderma	0.00247	0.0111	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Downstream TCR signaling—HLA-DQB1—systemic scleroderma	0.00247	0.0111	CbGpPWpGaD
Aminosalicylic Acid—Haemolytic anaemia—Mycophenolate mofetil—systemic scleroderma	0.00247	0.00461	CcSEcCtD
Aminosalicylic Acid—Abdominal distension—Mycophenolic acid—systemic scleroderma	0.00246	0.00459	CcSEcCtD
Aminosalicylic Acid—MPO—IL23-mediated signaling events—IL1B—systemic scleroderma	0.00243	0.0109	CbGpPWpGaD
Aminosalicylic Acid—Unspecified disorder of skin and subcutaneous tissue—Pentoxifylline—systemic scleroderma	0.00241	0.00451	CcSEcCtD
Aminosalicylic Acid—CHUK—Interleukin-1 signaling—IL1A—systemic scleroderma	0.0024	0.0107	CbGpPWpGaD
Aminosalicylic Acid—PLA2G2E—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	0.00234	0.0105	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Apoptosis—IRF5—systemic scleroderma	0.00234	0.0105	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—digestive system—systemic scleroderma	0.00234	0.0102	CbGeAlD
Aminosalicylic Acid—Weight decreased—Leflunomide—systemic scleroderma	0.00231	0.00432	CcSEcCtD
Aminosalicylic Acid—Hypoglycaemia—Mycophenolate mofetil—systemic scleroderma	0.00228	0.00426	CcSEcCtD
Aminosalicylic Acid—Thrombocytopenia—Pentoxifylline—systemic scleroderma	0.00228	0.00426	CcSEcCtD
Aminosalicylic Acid—PTGS1—Prostaglandin Synthesis and Regulation—EDN1—systemic scleroderma	0.00226	0.0101	CbGpPWpGaD
Aminosalicylic Acid—Skin disorder—Pentoxifylline—systemic scleroderma	0.00226	0.00422	CcSEcCtD
Aminosalicylic Acid—Agranulocytosis—Azathioprine—systemic scleroderma	0.00225	0.00421	CcSEcCtD
Aminosalicylic Acid—Neuropathy peripheral—Leflunomide—systemic scleroderma	0.00223	0.00417	CcSEcCtD
Aminosalicylic Acid—PTGS2—digestive system—systemic scleroderma	0.00223	0.00972	CbGeAlD
Aminosalicylic Acid—Gastrointestinal haemorrhage—Mycophenolate mofetil—systemic scleroderma	0.00223	0.00416	CcSEcCtD
Aminosalicylic Acid—PTGS1—tendon—systemic scleroderma	0.00222	0.00968	CbGeAlD
Aminosalicylic Acid—Jaundice—Leflunomide—systemic scleroderma	0.00222	0.00415	CcSEcCtD
Aminosalicylic Acid—Anorexia—Pentoxifylline—systemic scleroderma	0.00222	0.00415	CcSEcCtD
Aminosalicylic Acid—Weight decreased—Mycophenolic acid—systemic scleroderma	0.00221	0.00412	CcSEcCtD
Aminosalicylic Acid—CHUK—RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways—TNFAIP3—systemic scleroderma	0.00217	0.00973	CbGpPWpGaD
Aminosalicylic Acid—Neuropathy peripheral—Mycophenolic acid—systemic scleroderma	0.00213	0.00398	CcSEcCtD
Aminosalicylic Acid—Vasculitis—Prednisone—systemic scleroderma	0.00213	0.00398	CcSEcCtD
Aminosalicylic Acid—Agranulocytosis—Leflunomide—systemic scleroderma	0.00213	0.00397	CcSEcCtD
Aminosalicylic Acid—PTGS2—tendon—systemic scleroderma	0.00212	0.00925	CbGeAlD
Aminosalicylic Acid—Jaundice—Mycophenolic acid—systemic scleroderma	0.00212	0.00396	CcSEcCtD
Aminosalicylic Acid—Dysgeusia—Captopril—systemic scleroderma	0.00212	0.00395	CcSEcCtD
Aminosalicylic Acid—CHUK—TCR Signaling Pathway—CD247—systemic scleroderma	0.00211	0.00946	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Integrated Breast Cancer Pathway—SMAD7—systemic scleroderma	0.00211	0.00944	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Structural Pathway of Interleukin 1 (IL-1)—IL1A—systemic scleroderma	0.00211	0.00943	CbGpPWpGaD
Aminosalicylic Acid—Hepatitis—Leflunomide—systemic scleroderma	0.00205	0.00382	CcSEcCtD
Aminosalicylic Acid—CHUK—GAB1 signalosome—CSK—systemic scleroderma	0.00203	0.0091	CbGpPWpGaD
Aminosalicylic Acid—Agranulocytosis—Mycophenolic acid—systemic scleroderma	0.00203	0.00379	CcSEcCtD
Aminosalicylic Acid—Decreased appetite—Pentoxifylline—systemic scleroderma	0.00202	0.00378	CcSEcCtD
Aminosalicylic Acid—Urinary tract disorder—Leflunomide—systemic scleroderma	0.00202	0.00378	CcSEcCtD
Aminosalicylic Acid—MPO—Folate Metabolism—CCL2—systemic scleroderma	0.00201	0.00901	CbGpPWpGaD
Aminosalicylic Acid—Urethral disorder—Leflunomide—systemic scleroderma	0.00201	0.00375	CcSEcCtD
Aminosalicylic Acid—CHUK—Toll-like Receptor Signaling Pathway—IRF5—systemic scleroderma	0.002	0.00896	CbGpPWpGaD
Aminosalicylic Acid—Anaemia—Captopril—systemic scleroderma	0.002	0.00373	CcSEcCtD
Aminosalicylic Acid—Weight decreased—Lisinopril—systemic scleroderma	0.00199	0.00371	CcSEcCtD
Aminosalicylic Acid—CHUK—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.00196	0.00878	CbGpPWpGaD
Aminosalicylic Acid—Hepatitis—Mycophenolic acid—systemic scleroderma	0.00195	0.00365	CcSEcCtD
Aminosalicylic Acid—PTGS1—lung—systemic scleroderma	0.00195	0.00849	CbGeAlD
Aminosalicylic Acid—CHUK—TNF alpha Signaling Pathway—TNFAIP3—systemic scleroderma	0.00194	0.0087	CbGpPWpGaD
Aminosalicylic Acid—Abdominal distension—Mycophenolate mofetil—systemic scleroderma	0.00194	0.00362	CcSEcCtD
Aminosalicylic Acid—Urinary tract disorder—Mycophenolic acid—systemic scleroderma	0.00193	0.0036	CcSEcCtD
Aminosalicylic Acid—CHUK—Osteopontin-mediated events—MMP2—systemic scleroderma	0.00192	0.00861	CbGpPWpGaD
Aminosalicylic Acid—Neuropathy peripheral—Lisinopril—systemic scleroderma	0.00192	0.00359	CcSEcCtD
Aminosalicylic Acid—Anorexia—Mometasone—systemic scleroderma	0.00191	0.00358	CcSEcCtD
Aminosalicylic Acid—Urethral disorder—Mycophenolic acid—systemic scleroderma	0.00191	0.00358	CcSEcCtD
Aminosalicylic Acid—Jaundice—Lisinopril—systemic scleroderma	0.00191	0.00357	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal pain—Pentoxifylline—systemic scleroderma	0.0019	0.00356	CcSEcCtD
Aminosalicylic Acid—MPO—Vitamin B12 Metabolism—IL1B—systemic scleroderma	0.00188	0.0084	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—lung—systemic scleroderma	0.00186	0.00812	CbGeAlD
Aminosalicylic Acid—CHUK—IL-1 signaling pathway—IL1A—systemic scleroderma	0.00186	0.00832	CbGpPWpGaD
Aminosalicylic Acid—Urticaria—Pentoxifylline—systemic scleroderma	0.00185	0.00345	CcSEcCtD
Aminosalicylic Acid—CHUK—TCR signaling—HLA-DQB1—systemic scleroderma	0.00185	0.00828	CbGpPWpGaD
Aminosalicylic Acid—CHUK—B Cell Receptor Signaling Pathway—BLK—systemic scleroderma	0.00184	0.00824	CbGpPWpGaD
Aminosalicylic Acid—Body temperature increased—Pentoxifylline—systemic scleroderma	0.00184	0.00344	CcSEcCtD
Aminosalicylic Acid—Abdominal pain—Pentoxifylline—systemic scleroderma	0.00184	0.00344	CcSEcCtD
Aminosalicylic Acid—Agranulocytosis—Lisinopril—systemic scleroderma	0.00183	0.00342	CcSEcCtD
Aminosalicylic Acid—PTGS2—Calcium signaling in the CD4+ TCR pathway—CD40LG—systemic scleroderma	0.00183	0.00817	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Prostaglandin Synthesis and Regulation—EDN1—systemic scleroderma	0.0018	0.00805	CbGpPWpGaD
Aminosalicylic Acid—Malnutrition—Leflunomide—systemic scleroderma	0.00178	0.00333	CcSEcCtD
Aminosalicylic Acid—Vasculitis—Methotrexate—systemic scleroderma	0.00178	0.00333	CcSEcCtD
Aminosalicylic Acid—PLA2G2E—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	0.00177	0.00793	CbGpPWpGaD
Aminosalicylic Acid—Hepatitis—Lisinopril—systemic scleroderma	0.00176	0.00329	CcSEcCtD
Aminosalicylic Acid—Flatulence—Leflunomide—systemic scleroderma	0.00176	0.00328	CcSEcCtD
Aminosalicylic Acid—Decreased appetite—Mometasone—systemic scleroderma	0.00175	0.00326	CcSEcCtD
Aminosalicylic Acid—Dysgeusia—Leflunomide—systemic scleroderma	0.00174	0.00326	CcSEcCtD
Aminosalicylic Acid—Anaemia—Azathioprine—systemic scleroderma	0.00174	0.00326	CcSEcCtD
Aminosalicylic Acid—Weight decreased—Mycophenolate mofetil—systemic scleroderma	0.00174	0.00325	CcSEcCtD
Aminosalicylic Acid—Urinary tract disorder—Lisinopril—systemic scleroderma	0.00174	0.00324	CcSEcCtD
Aminosalicylic Acid—Thrombocytopenia—Captopril—systemic scleroderma	0.00173	0.00323	CcSEcCtD
Aminosalicylic Acid—Urethral disorder—Lisinopril—systemic scleroderma	0.00172	0.00322	CcSEcCtD
Aminosalicylic Acid—Hypersensitivity—Pentoxifylline—systemic scleroderma	0.00172	0.0032	CcSEcCtD
Aminosalicylic Acid—Malnutrition—Mycophenolic acid—systemic scleroderma	0.0017	0.00318	CcSEcCtD
Aminosalicylic Acid—Leukopenia—Azathioprine—systemic scleroderma	0.00169	0.00315	CcSEcCtD
Aminosalicylic Acid—Vascular purpura—Prednisone—systemic scleroderma	0.00169	0.00315	CcSEcCtD
Aminosalicylic Acid—Neuropathy peripheral—Mycophenolate mofetil—systemic scleroderma	0.00168	0.00314	CcSEcCtD
Aminosalicylic Acid—Anorexia—Captopril—systemic scleroderma	0.00168	0.00314	CcSEcCtD
Aminosalicylic Acid—Flatulence—Mycophenolic acid—systemic scleroderma	0.00167	0.00313	CcSEcCtD
Aminosalicylic Acid—Jaundice—Mycophenolate mofetil—systemic scleroderma	0.00167	0.00313	CcSEcCtD
Aminosalicylic Acid—CHUK—Toll Like Receptor 4 (TLR4) Cascade—ITGAM—systemic scleroderma	0.00166	0.00742	CbGpPWpGaD
Aminosalicylic Acid—Anaemia—Leflunomide—systemic scleroderma	0.00165	0.00308	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal pain—Mometasone—systemic scleroderma	0.00164	0.00307	CcSEcCtD
Aminosalicylic Acid—Agranulocytosis—Mycophenolate mofetil—systemic scleroderma	0.0016	0.00299	CcSEcCtD
Aminosalicylic Acid—MPO—Selenium Micronutrient Network—CCL2—systemic scleroderma	0.0016	0.00716	CbGpPWpGaD
Aminosalicylic Acid—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—systemic scleroderma	0.0016	0.00298	CcSEcCtD
Aminosalicylic Acid—Leukopenia—Leflunomide—systemic scleroderma	0.00159	0.00298	CcSEcCtD
Aminosalicylic Acid—Diarrhoea—Pentoxifylline—systemic scleroderma	0.00159	0.00298	CcSEcCtD
Aminosalicylic Acid—Abdominal pain—Mometasone—systemic scleroderma	0.00159	0.00297	CcSEcCtD
Aminosalicylic Acid—Body temperature increased—Mometasone—systemic scleroderma	0.00159	0.00297	CcSEcCtD
Aminosalicylic Acid—CHUK—TWEAK Signaling Pathway—CCL2—systemic scleroderma	0.00158	0.00709	CbGpPWpGaD
Aminosalicylic Acid—Anaemia—Mycophenolic acid—systemic scleroderma	0.00157	0.00293	CcSEcCtD
Aminosalicylic Acid—Purpura—Prednisone—systemic scleroderma	0.00157	0.00293	CcSEcCtD
Aminosalicylic Acid—CHUK—Regulation of toll-like receptor signaling pathway—IRF5—systemic scleroderma	0.00156	0.00699	CbGpPWpGaD
Aminosalicylic Acid—Hepatitis—Mycophenolate mofetil—systemic scleroderma	0.00154	0.00288	CcSEcCtD
Aminosalicylic Acid—Dizziness—Pentoxifylline—systemic scleroderma	0.00154	0.00288	CcSEcCtD
Aminosalicylic Acid—Decreased appetite—Captopril—systemic scleroderma	0.00153	0.00286	CcSEcCtD
Aminosalicylic Acid—Malnutrition—Lisinopril—systemic scleroderma	0.00153	0.00286	CcSEcCtD
Aminosalicylic Acid—MPO—Folate Metabolism—IL1B—systemic scleroderma	0.00153	0.00683	CbGpPWpGaD
Aminosalicylic Acid—Urinary tract disorder—Mycophenolate mofetil—systemic scleroderma	0.00152	0.00284	CcSEcCtD
Aminosalicylic Acid—Leukopenia—Mycophenolic acid—systemic scleroderma	0.00152	0.00284	CcSEcCtD
Aminosalicylic Acid—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CTLA4—systemic scleroderma	0.00152	0.0068	CbGpPWpGaD
Aminosalicylic Acid—Urethral disorder—Mycophenolate mofetil—systemic scleroderma	0.00151	0.00282	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal haemorrhage—Prednisone—systemic scleroderma	0.00151	0.00282	CcSEcCtD
Aminosalicylic Acid—ALOX5—Selenium Micronutrient Network—CCL2—systemic scleroderma	0.00151	0.00676	CbGpPWpGaD
Aminosalicylic Acid—Flatulence—Lisinopril—systemic scleroderma	0.00151	0.00282	CcSEcCtD
Aminosalicylic Acid—Thrombocytopenia—Azathioprine—systemic scleroderma	0.00151	0.00282	CcSEcCtD
Aminosalicylic Acid—Unspecified disorder of skin and subcutaneous tissue—Leflunomide—systemic scleroderma	0.00151	0.00281	CcSEcCtD
Aminosalicylic Acid—Dysgeusia—Lisinopril—systemic scleroderma	0.0015	0.0028	CcSEcCtD
Aminosalicylic Acid—Skin disorder—Azathioprine—systemic scleroderma	0.0015	0.00279	CcSEcCtD
Aminosalicylic Acid—Vomiting—Pentoxifylline—systemic scleroderma	0.00148	0.00277	CcSEcCtD
Aminosalicylic Acid—CHUK—Toll-Like Receptors Cascades—ITGAM—systemic scleroderma	0.00148	0.00661	CbGpPWpGaD
Aminosalicylic Acid—Rash—Pentoxifylline—systemic scleroderma	0.00147	0.00274	CcSEcCtD
Aminosalicylic Acid—Dermatitis—Pentoxifylline—systemic scleroderma	0.00147	0.00274	CcSEcCtD
Aminosalicylic Acid—Headache—Pentoxifylline—systemic scleroderma	0.00146	0.00272	CcSEcCtD
Aminosalicylic Acid—PTGS2—C-MYB transcription factor network—COL1A2—systemic scleroderma	0.00146	0.00652	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Osteopontin-mediated events—MMP9—systemic scleroderma	0.00145	0.00647	CbGpPWpGaD
Aminosalicylic Acid—Gastrointestinal pain—Captopril—systemic scleroderma	0.00144	0.0027	CcSEcCtD
Aminosalicylic Acid—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.00144	0.00268	CcSEcCtD
Aminosalicylic Acid—Nervous system disorder—Leflunomide—systemic scleroderma	0.00143	0.00266	CcSEcCtD
Aminosalicylic Acid—Thrombocytopenia—Leflunomide—systemic scleroderma	0.00142	0.00266	CcSEcCtD
Aminosalicylic Acid—CHUK—IL1-mediated signaling events—IL1B—systemic scleroderma	0.00142	0.00637	CbGpPWpGaD
Aminosalicylic Acid—Anaemia—Lisinopril—systemic scleroderma	0.00141	0.00264	CcSEcCtD
Aminosalicylic Acid—PTGS2—Spinal Cord Injury—TNFSF13—systemic scleroderma	0.00141	0.00633	CbGpPWpGaD
Aminosalicylic Acid—Skin disorder—Leflunomide—systemic scleroderma	0.00141	0.00264	CcSEcCtD
Aminosalicylic Acid—CHUK—Regulation of toll-like receptor signaling pathway—TNFAIP3—systemic scleroderma	0.0014	0.00626	CbGpPWpGaD
Aminosalicylic Acid—Abdominal pain—Captopril—systemic scleroderma	0.00139	0.00261	CcSEcCtD
Aminosalicylic Acid—Body temperature increased—Captopril—systemic scleroderma	0.00139	0.00261	CcSEcCtD
Aminosalicylic Acid—Anorexia—Leflunomide—systemic scleroderma	0.00139	0.00259	CcSEcCtD
Aminosalicylic Acid—Nausea—Pentoxifylline—systemic scleroderma	0.00138	0.00258	CcSEcCtD
Aminosalicylic Acid—Diarrhoea—Mometasone—systemic scleroderma	0.00137	0.00257	CcSEcCtD
Aminosalicylic Acid—Leukopenia—Lisinopril—systemic scleroderma	0.00137	0.00256	CcSEcCtD
Aminosalicylic Acid—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.00136	0.00254	CcSEcCtD
Aminosalicylic Acid—Thrombocytopenia—Mycophenolic acid—systemic scleroderma	0.00136	0.00254	CcSEcCtD
Aminosalicylic Acid—Skin disorder—Mycophenolic acid—systemic scleroderma	0.00135	0.00252	CcSEcCtD
Aminosalicylic Acid—Malnutrition—Mycophenolate mofetil—systemic scleroderma	0.00134	0.00251	CcSEcCtD
Aminosalicylic Acid—Dermatitis exfoliative—Methotrexate—systemic scleroderma	0.00134	0.0025	CcSEcCtD
Aminosalicylic Acid—CHUK—MicroRNAs in cardiomyocyte hypertrophy—EDN1—systemic scleroderma	0.00133	0.00596	CbGpPWpGaD
Aminosalicylic Acid—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.00133	0.00248	CcSEcCtD
Aminosalicylic Acid—Anorexia—Mycophenolic acid—systemic scleroderma	0.00132	0.00247	CcSEcCtD
Aminosalicylic Acid—Flatulence—Mycophenolate mofetil—systemic scleroderma	0.00132	0.00247	CcSEcCtD
Aminosalicylic Acid—Abdominal distension—Prednisone—systemic scleroderma	0.00131	0.00245	CcSEcCtD
Aminosalicylic Acid—Dysgeusia—Mycophenolate mofetil—systemic scleroderma	0.00131	0.00245	CcSEcCtD
Aminosalicylic Acid—CHUK—Signaling by EGFR—CSK—systemic scleroderma	0.0013	0.0058	CbGpPWpGaD
Aminosalicylic Acid—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.00129	0.00242	CcSEcCtD
Aminosalicylic Acid—CHUK—Signaling by EGFR in Cancer—CSK—systemic scleroderma	0.00129	0.00575	CbGpPWpGaD
Aminosalicylic Acid—CHUK—IL-1 signaling pathway—CCL2—systemic scleroderma	0.00128	0.00572	CbGpPWpGaD
Aminosalicylic Acid—Vomiting—Mometasone—systemic scleroderma	0.00128	0.00239	CcSEcCtD
Aminosalicylic Acid—Rash—Mometasone—systemic scleroderma	0.00127	0.00237	CcSEcCtD
Aminosalicylic Acid—Dermatitis—Mometasone—systemic scleroderma	0.00127	0.00236	CcSEcCtD
Aminosalicylic Acid—Decreased appetite—Leflunomide—systemic scleroderma	0.00126	0.00236	CcSEcCtD
Aminosalicylic Acid—PTGS2—Spinal Cord Injury—SELP—systemic scleroderma	0.00126	0.00564	CbGpPWpGaD
Aminosalicylic Acid—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.00126	0.00235	CcSEcCtD
Aminosalicylic Acid—Headache—Mometasone—systemic scleroderma	0.00126	0.00235	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.00126	0.00235	CcSEcCtD
Aminosalicylic Acid—CHUK—TCR Signaling Pathway—IL1A—systemic scleroderma	0.00125	0.00561	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Interleukin-1 signaling—IL1B—systemic scleroderma	0.00125	0.00559	CbGpPWpGaD
Aminosalicylic Acid—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.00124	0.00232	CcSEcCtD
Aminosalicylic Acid—CHUK—NOD pathway—IL1B—systemic scleroderma	0.00123	0.00549	CbGpPWpGaD
Aminosalicylic Acid—Thrombocytopenia—Lisinopril—systemic scleroderma	0.00122	0.00229	CcSEcCtD
Aminosalicylic Acid—Abdominal pain—Azathioprine—systemic scleroderma	0.00122	0.00227	CcSEcCtD
Aminosalicylic Acid—Body temperature increased—Azathioprine—systemic scleroderma	0.00122	0.00227	CcSEcCtD
Aminosalicylic Acid—Skin disorder—Lisinopril—systemic scleroderma	0.00121	0.00227	CcSEcCtD
Aminosalicylic Acid—MPO—Selenium Micronutrient Network—IL1B—systemic scleroderma	0.00121	0.00543	CbGpPWpGaD
Aminosalicylic Acid—Diarrhoea—Captopril—systemic scleroderma	0.00121	0.00225	CcSEcCtD
Aminosalicylic Acid—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.00121	0.00225	CcSEcCtD
Aminosalicylic Acid—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.0012	0.00224	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.0012	0.00224	CcSEcCtD
Aminosalicylic Acid—Nausea—Mometasone—systemic scleroderma	0.00119	0.00223	CcSEcCtD
Aminosalicylic Acid—Anorexia—Lisinopril—systemic scleroderma	0.00119	0.00222	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.00119	0.00222	CcSEcCtD
Aminosalicylic Acid—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—systemic scleroderma	0.00118	0.00529	CbGpPWpGaD
Aminosalicylic Acid—Weight decreased—Prednisone—systemic scleroderma	0.00118	0.00221	CcSEcCtD
Aminosalicylic Acid—PTGS2—Spinal Cord Injury—RHOB—systemic scleroderma	0.00118	0.00527	CbGpPWpGaD
Aminosalicylic Acid—Dizziness—Captopril—systemic scleroderma	0.00117	0.00218	CcSEcCtD
Aminosalicylic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.00116	0.0052	CbGpPWpGaD
Aminosalicylic Acid—Urticaria—Leflunomide—systemic scleroderma	0.00116	0.00216	CcSEcCtD
Aminosalicylic Acid—Abdominal pain—Leflunomide—systemic scleroderma	0.00115	0.00215	CcSEcCtD
Aminosalicylic Acid—Body temperature increased—Leflunomide—systemic scleroderma	0.00115	0.00215	CcSEcCtD
Aminosalicylic Acid—ALOX5—Selenium Micronutrient Network—IL1B—systemic scleroderma	0.00114	0.00512	CbGpPWpGaD
Aminosalicylic Acid—Neuropathy peripheral—Prednisone—systemic scleroderma	0.00114	0.00213	CcSEcCtD
Aminosalicylic Acid—Hypersensitivity—Azathioprine—systemic scleroderma	0.00113	0.00212	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.00113	0.00212	CcSEcCtD
Aminosalicylic Acid—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.00113	0.00212	CcSEcCtD
Aminosalicylic Acid—CHUK—TWEAK Signaling Pathway—MMP9—systemic scleroderma	0.00113	0.00507	CbGpPWpGaD
Aminosalicylic Acid—Vomiting—Captopril—systemic scleroderma	0.00112	0.0021	CcSEcCtD
Aminosalicylic Acid—Rash—Captopril—systemic scleroderma	0.00111	0.00208	CcSEcCtD
Aminosalicylic Acid—Dermatitis—Captopril—systemic scleroderma	0.00111	0.00208	CcSEcCtD
Aminosalicylic Acid—Headache—Captopril—systemic scleroderma	0.00111	0.00206	CcSEcCtD
Aminosalicylic Acid—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.0011	0.00205	CcSEcCtD
Aminosalicylic Acid—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.0011	0.00205	CcSEcCtD
Aminosalicylic Acid—Decreased appetite—Lisinopril—systemic scleroderma	0.00109	0.00203	CcSEcCtD
Aminosalicylic Acid—CHUK—Signaling by Interleukins—IL1A—systemic scleroderma	0.00108	0.00485	CbGpPWpGaD
Aminosalicylic Acid—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.00108	0.00202	CcSEcCtD
Aminosalicylic Acid—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.00107	0.00201	CcSEcCtD
Aminosalicylic Acid—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.00107	0.002	CcSEcCtD
Aminosalicylic Acid—Hypersensitivity—Leflunomide—systemic scleroderma	0.00107	0.002	CcSEcCtD
Aminosalicylic Acid—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.00106	0.00199	CcSEcCtD
Aminosalicylic Acid—CHUK—B Cell Activation—BLK—systemic scleroderma	0.00105	0.00472	CbGpPWpGaD
Aminosalicylic Acid—Diarrhoea—Azathioprine—systemic scleroderma	0.00105	0.00197	CcSEcCtD
Aminosalicylic Acid—CHUK—AGE/RAGE pathway—MMP2—systemic scleroderma	0.00105	0.0047	CbGpPWpGaD
Aminosalicylic Acid—Nausea—Captopril—systemic scleroderma	0.00105	0.00196	CcSEcCtD
Aminosalicylic Acid—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.00104	0.00195	CcSEcCtD
Aminosalicylic Acid—PLA2G2E—Metabolism—HSPG2—systemic scleroderma	0.00104	0.00466	CbGpPWpGaD
Aminosalicylic Acid—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.00102	0.00191	CcSEcCtD
Aminosalicylic Acid—Dizziness—Azathioprine—systemic scleroderma	0.00102	0.0019	CcSEcCtD
Aminosalicylic Acid—Diarrhoea—Leflunomide—systemic scleroderma	0.000995	0.00186	CcSEcCtD
Aminosalicylic Acid—Urticaria—Lisinopril—systemic scleroderma	0.000993	0.00185	CcSEcCtD
Aminosalicylic Acid—Abdominal pain—Lisinopril—systemic scleroderma	0.000988	0.00185	CcSEcCtD
Aminosalicylic Acid—Body temperature increased—Lisinopril—systemic scleroderma	0.000988	0.00185	CcSEcCtD
Aminosalicylic Acid—CHUK—AGE/RAGE pathway—NOS3—systemic scleroderma	0.000984	0.0044	CbGpPWpGaD
Aminosalicylic Acid—Vomiting—Azathioprine—systemic scleroderma	0.000979	0.00183	CcSEcCtD
Aminosalicylic Acid—Rash—Azathioprine—systemic scleroderma	0.000971	0.00181	CcSEcCtD
Aminosalicylic Acid—Dermatitis—Azathioprine—systemic scleroderma	0.00097	0.00181	CcSEcCtD
Aminosalicylic Acid—CHUK—IL-1 signaling pathway—IL1B—systemic scleroderma	0.000969	0.00434	CbGpPWpGaD
Aminosalicylic Acid—Headache—Azathioprine—systemic scleroderma	0.000965	0.0018	CcSEcCtD
Aminosalicylic Acid—Dizziness—Leflunomide—systemic scleroderma	0.000961	0.0018	CcSEcCtD
Aminosalicylic Acid—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000952	0.00178	CcSEcCtD
Aminosalicylic Acid—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000949	0.00177	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000945	0.00177	CcSEcCtD
Aminosalicylic Acid—Vomiting—Leflunomide—systemic scleroderma	0.000924	0.00173	CcSEcCtD
Aminosalicylic Acid—Hypersensitivity—Lisinopril—systemic scleroderma	0.00092	0.00172	CcSEcCtD
Aminosalicylic Acid—Dizziness—Mycophenolic acid—systemic scleroderma	0.000917	0.00171	CcSEcCtD
Aminosalicylic Acid—Rash—Leflunomide—systemic scleroderma	0.000917	0.00171	CcSEcCtD
Aminosalicylic Acid—ALOX5—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	0.000916	0.0041	CbGpPWpGaD
Aminosalicylic Acid—Dermatitis—Leflunomide—systemic scleroderma	0.000916	0.00171	CcSEcCtD
Aminosalicylic Acid—Nausea—Azathioprine—systemic scleroderma	0.000915	0.00171	CcSEcCtD
Aminosalicylic Acid—Headache—Leflunomide—systemic scleroderma	0.000911	0.0017	CcSEcCtD
Aminosalicylic Acid—Malnutrition—Prednisone—systemic scleroderma	0.000909	0.0017	CcSEcCtD
Aminosalicylic Acid—Agranulocytosis—Methotrexate—systemic scleroderma	0.000907	0.0017	CcSEcCtD
Aminosalicylic Acid—CHUK—Interleukin-11 Signaling Pathway—TGFB1—systemic scleroderma	0.0009	0.00403	CbGpPWpGaD
Aminosalicylic Acid—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000895	0.00167	CcSEcCtD
Aminosalicylic Acid—CHUK—Cytokine Signaling in Immune system—IRF5—systemic scleroderma	0.000892	0.00399	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Leptin signaling pathway—NOS3—systemic scleroderma	0.000888	0.00398	CbGpPWpGaD
Aminosalicylic Acid—Vomiting—Mycophenolic acid—systemic scleroderma	0.000882	0.00165	CcSEcCtD
Aminosalicylic Acid—Rash—Mycophenolic acid—systemic scleroderma	0.000875	0.00163	CcSEcCtD
Aminosalicylic Acid—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000874	0.00163	CcSEcCtD
Aminosalicylic Acid—Hepatitis—Methotrexate—systemic scleroderma	0.000873	0.00163	CcSEcCtD
Aminosalicylic Acid—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.00087	0.00162	CcSEcCtD
Aminosalicylic Acid—Headache—Mycophenolic acid—systemic scleroderma	0.000869	0.00162	CcSEcCtD
Aminosalicylic Acid—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000865	0.00162	CcSEcCtD
Aminosalicylic Acid—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000865	0.00162	CcSEcCtD
Aminosalicylic Acid—Nausea—Leflunomide—systemic scleroderma	0.000864	0.00161	CcSEcCtD
Aminosalicylic Acid—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000862	0.00161	CcSEcCtD
Aminosalicylic Acid—Urethral disorder—Methotrexate—systemic scleroderma	0.000856	0.0016	CcSEcCtD
Aminosalicylic Acid—Diarrhoea—Lisinopril—systemic scleroderma	0.000855	0.0016	CcSEcCtD
Aminosalicylic Acid—CHUK—Cytokine Signaling in Immune system—IRF8—systemic scleroderma	0.000852	0.00382	CbGpPWpGaD
Aminosalicylic Acid—CHUK—TNF alpha Signaling Pathway—CCL2—systemic scleroderma	0.000846	0.00379	CbGpPWpGaD
Aminosalicylic Acid—Anaemia—Prednisone—systemic scleroderma	0.00084	0.00157	CcSEcCtD
Aminosalicylic Acid—Dizziness—Lisinopril—systemic scleroderma	0.000826	0.00154	CcSEcCtD
Aminosalicylic Acid—Nausea—Mycophenolic acid—systemic scleroderma	0.000824	0.00154	CcSEcCtD
Aminosalicylic Acid—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000806	0.00151	CcSEcCtD
Aminosalicylic Acid—Vomiting—Lisinopril—systemic scleroderma	0.000794	0.00148	CcSEcCtD
Aminosalicylic Acid—CHUK—AGE/RAGE pathway—MMP9—systemic scleroderma	0.000789	0.00353	CbGpPWpGaD
Aminosalicylic Acid—PLA2G2E—Metabolism—CTGF—systemic scleroderma	0.000789	0.00353	CbGpPWpGaD
Aminosalicylic Acid—Rash—Lisinopril—systemic scleroderma	0.000788	0.00147	CcSEcCtD
Aminosalicylic Acid—Dermatitis—Lisinopril—systemic scleroderma	0.000787	0.00147	CcSEcCtD
Aminosalicylic Acid—Headache—Lisinopril—systemic scleroderma	0.000783	0.00146	CcSEcCtD
Aminosalicylic Acid—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000769	0.00144	CcSEcCtD
Aminosalicylic Acid—Malnutrition—Methotrexate—systemic scleroderma	0.00076	0.00142	CcSEcCtD
Aminosalicylic Acid—CHUK—Leptin signaling pathway—IL1B—systemic scleroderma	0.000756	0.00338	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Cardiac Hypertrophic Response—TGFB1—systemic scleroderma	0.000753	0.00337	CbGpPWpGaD
Aminosalicylic Acid—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000749	0.0014	CcSEcCtD
Aminosalicylic Acid—Dysgeusia—Methotrexate—systemic scleroderma	0.000744	0.00139	CcSEcCtD
Aminosalicylic Acid—Nausea—Lisinopril—systemic scleroderma	0.000742	0.00139	CcSEcCtD
Aminosalicylic Acid—Nervous system disorder—Prednisone—systemic scleroderma	0.000728	0.00136	CcSEcCtD
Aminosalicylic Acid—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000724	0.00135	CcSEcCtD
Aminosalicylic Acid—Skin disorder—Prednisone—systemic scleroderma	0.000721	0.00135	CcSEcCtD
Aminosalicylic Acid—Anorexia—Prednisone—systemic scleroderma	0.000707	0.00132	CcSEcCtD
Aminosalicylic Acid—Anaemia—Methotrexate—systemic scleroderma	0.000702	0.00131	CcSEcCtD
Aminosalicylic Acid—CHUK—Integrated Breast Cancer Pathway—MMP1—systemic scleroderma	0.0007	0.00313	CbGpPWpGaD
Aminosalicylic Acid—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000696	0.0013	CcSEcCtD
Aminosalicylic Acid—ALOX5—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	0.000694	0.00311	CbGpPWpGaD
Aminosalicylic Acid—Rash—Mycophenolate mofetil—systemic scleroderma	0.00069	0.00129	CcSEcCtD
Aminosalicylic Acid—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.00069	0.00129	CcSEcCtD
Aminosalicylic Acid—Headache—Mycophenolate mofetil—systemic scleroderma	0.000686	0.00128	CcSEcCtD
Aminosalicylic Acid—Leukopenia—Methotrexate—systemic scleroderma	0.00068	0.00127	CcSEcCtD
Aminosalicylic Acid—PTGS1—Selenium Micronutrient Network—CCL2—systemic scleroderma	0.000654	0.00293	CbGpPWpGaD
Aminosalicylic Acid—CHUK—TCR Signaling Pathway—IL1B—systemic scleroderma	0.000653	0.00292	CbGpPWpGaD
Aminosalicylic Acid—Nausea—Mycophenolate mofetil—systemic scleroderma	0.00065	0.00121	CcSEcCtD
Aminosalicylic Acid—Decreased appetite—Prednisone—systemic scleroderma	0.000645	0.00121	CcSEcCtD
Aminosalicylic Acid—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000642	0.0012	CcSEcCtD
Aminosalicylic Acid—Nervous system disorder—Methotrexate—systemic scleroderma	0.000608	0.00114	CcSEcCtD
Aminosalicylic Acid—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000607	0.00113	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000607	0.00113	CcSEcCtD
Aminosalicylic Acid—Skin disorder—Methotrexate—systemic scleroderma	0.000602	0.00113	CcSEcCtD
Aminosalicylic Acid—PTGS2—Spinal Cord Injury—IL1A—systemic scleroderma	0.000597	0.00267	CbGpPWpGaD
Aminosalicylic Acid—Anorexia—Methotrexate—systemic scleroderma	0.000591	0.0011	CcSEcCtD
Aminosalicylic Acid—CHUK—Toll-like Receptor Signaling Pathway—IL1B—systemic scleroderma	0.000591	0.00265	CbGpPWpGaD
Aminosalicylic Acid—Urticaria—Prednisone—systemic scleroderma	0.000589	0.0011	CcSEcCtD
Aminosalicylic Acid—Abdominal pain—Prednisone—systemic scleroderma	0.000587	0.0011	CcSEcCtD
Aminosalicylic Acid—Body temperature increased—Prednisone—systemic scleroderma	0.000587	0.0011	CcSEcCtD
Aminosalicylic Acid—CHUK—Signaling by Interleukins—IL1B—systemic scleroderma	0.000565	0.00253	CbGpPWpGaD
Aminosalicylic Acid—Hypersensitivity—Prednisone—systemic scleroderma	0.000547	0.00102	CcSEcCtD
Aminosalicylic Acid—Decreased appetite—Methotrexate—systemic scleroderma	0.000539	0.00101	CcSEcCtD
Aminosalicylic Acid—CHUK—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—systemic scleroderma	0.000536	0.0024	CbGpPWpGaD
Aminosalicylic Acid—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000535	0.001	CcSEcCtD
Aminosalicylic Acid—CHUK—Cytokine Signaling in Immune system—HLA-DQB1—systemic scleroderma	0.000532	0.00238	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Selenium Micronutrient Network—CCL2—systemic scleroderma	0.00052	0.00233	CbGpPWpGaD
Aminosalicylic Acid—Diarrhoea—Prednisone—systemic scleroderma	0.000508	0.000948	CcSEcCtD
Aminosalicylic Acid—CHUK—TCR Signaling Pathway—TGFB1—systemic scleroderma	0.000508	0.00227	CbGpPWpGaD
Aminosalicylic Acid—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000507	0.000947	CcSEcCtD
Aminosalicylic Acid—CHUK—Cytokine Signaling in Immune system—IL1A—systemic scleroderma	0.000505	0.00226	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Selenium Micronutrient Network—IL1B—systemic scleroderma	0.000496	0.00222	CbGpPWpGaD
Aminosalicylic Acid—Urticaria—Methotrexate—systemic scleroderma	0.000493	0.00092	CcSEcCtD
Aminosalicylic Acid—Dizziness—Prednisone—systemic scleroderma	0.000491	0.000917	CcSEcCtD
Aminosalicylic Acid—Body temperature increased—Methotrexate—systemic scleroderma	0.00049	0.000916	CcSEcCtD
Aminosalicylic Acid—Abdominal pain—Methotrexate—systemic scleroderma	0.00049	0.000916	CcSEcCtD
Aminosalicylic Acid—CHUK—Adaptive Immune System—CSK—systemic scleroderma	0.000488	0.00219	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Innate Immune System—ITGAM—systemic scleroderma	0.000478	0.00214	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Innate Immune System—CD247—systemic scleroderma	0.000478	0.00214	CbGpPWpGaD
Aminosalicylic Acid—Vomiting—Prednisone—systemic scleroderma	0.000472	0.000881	CcSEcCtD
Aminosalicylic Acid—Rash—Prednisone—systemic scleroderma	0.000468	0.000874	CcSEcCtD
Aminosalicylic Acid—Dermatitis—Prednisone—systemic scleroderma	0.000467	0.000873	CcSEcCtD
Aminosalicylic Acid—Headache—Prednisone—systemic scleroderma	0.000465	0.000868	CcSEcCtD
Aminosalicylic Acid—CHUK—Regulation of toll-like receptor signaling pathway—IL1B—systemic scleroderma	0.000461	0.00207	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Adaptive Immune System—CD247—systemic scleroderma	0.000459	0.00205	CbGpPWpGaD
Aminosalicylic Acid—Hypersensitivity—Methotrexate—systemic scleroderma	0.000457	0.000854	CcSEcCtD
Aminosalicylic Acid—CHUK—Innate Immune System—TNFAIP3—systemic scleroderma	0.000448	0.002	CbGpPWpGaD
Aminosalicylic Acid—Nausea—Prednisone—systemic scleroderma	0.000441	0.000823	CcSEcCtD
Aminosalicylic Acid—CHUK—Signaling by SCF-KIT—MMP9—systemic scleroderma	0.00043	0.00193	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Adaptive Immune System—BLK—systemic scleroderma	0.000425	0.0019	CbGpPWpGaD
Aminosalicylic Acid—Diarrhoea—Methotrexate—systemic scleroderma	0.000424	0.000793	CcSEcCtD
Aminosalicylic Acid—PTGS2—Spinal Cord Injury—CCL2—systemic scleroderma	0.000411	0.00184	CbGpPWpGaD
Aminosalicylic Acid—Dizziness—Methotrexate—systemic scleroderma	0.00041	0.000766	CcSEcCtD
Aminosalicylic Acid—ALOX5—Metabolism—HSPG2—systemic scleroderma	0.000408	0.00183	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	0.000397	0.00178	CbGpPWpGaD
Aminosalicylic Acid—Vomiting—Methotrexate—systemic scleroderma	0.000394	0.000737	CcSEcCtD
Aminosalicylic Acid—PTGS2—Selenium Micronutrient Network—IL1B—systemic scleroderma	0.000394	0.00176	CbGpPWpGaD
Aminosalicylic Acid—Rash—Methotrexate—systemic scleroderma	0.000391	0.00073	CcSEcCtD
Aminosalicylic Acid—Dermatitis—Methotrexate—systemic scleroderma	0.000391	0.00073	CcSEcCtD
Aminosalicylic Acid—Headache—Methotrexate—systemic scleroderma	0.000388	0.000726	CcSEcCtD
Aminosalicylic Acid—CHUK—Disease—SMAD7—systemic scleroderma	0.000388	0.00174	CbGpPWpGaD
Aminosalicylic Acid—Nausea—Methotrexate—systemic scleroderma	0.000368	0.000688	CcSEcCtD
Aminosalicylic Acid—CHUK—Disease—TGFBI—systemic scleroderma	0.000355	0.00159	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Adaptive Immune System—CTLA4—systemic scleroderma	0.000348	0.00156	CbGpPWpGaD
Aminosalicylic Acid—PLA2G2E—Metabolism—NOS3—systemic scleroderma	0.000343	0.00154	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	0.000315	0.00141	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Spinal Cord Injury—IL1B—systemic scleroderma	0.000312	0.00139	CbGpPWpGaD
Aminosalicylic Acid—ALOX5—Metabolism—CTGF—systemic scleroderma	0.000309	0.00138	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	0.000301	0.00135	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—CSK—systemic scleroderma	0.000296	0.00133	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Spinal Cord Injury—MMP9—systemic scleroderma	0.000294	0.00132	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—IRF5—systemic scleroderma	0.000291	0.0013	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Adaptive Immune System—HLA-DQB1—systemic scleroderma	0.000286	0.00128	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—HSPG2—systemic scleroderma	0.000283	0.00127	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—IRF8—systemic scleroderma	0.000278	0.00125	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—ITGAM—systemic scleroderma	0.000278	0.00125	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—CD247—systemic scleroderma	0.000278	0.00125	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	0.000278	0.00124	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—CSK—systemic scleroderma	0.000273	0.00122	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—SMAD7—systemic scleroderma	0.000272	0.00122	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Adaptive Immune System—CD40LG—systemic scleroderma	0.000271	0.00121	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Cytokine Signaling in Immune system—IL1B—systemic scleroderma	0.000264	0.00118	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—TNFAIP3—systemic scleroderma	0.000261	0.00117	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—BLK—systemic scleroderma	0.000258	0.00115	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—CD247—systemic scleroderma	0.000257	0.00115	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Spinal Cord Injury—TGFB1—systemic scleroderma	0.000242	0.00108	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	0.000239	0.00107	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—SMAD7—systemic scleroderma	0.00023	0.00103	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—CTLA4—systemic scleroderma	0.000211	0.000944	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—TGFBI—systemic scleroderma	0.00021	0.000941	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—RHOB—systemic scleroderma	0.00021	0.000941	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—HSPG2—systemic scleroderma	0.000198	0.000887	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—CSK—systemic scleroderma	0.000191	0.000857	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism—HSPG2—systemic scleroderma	0.000177	0.000792	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—HLA-DQB1—systemic scleroderma	0.000174	0.000778	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—HSPG2—systemic scleroderma	0.000168	0.000751	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—IL1A—systemic scleroderma	0.000165	0.000739	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	0.000165	0.000737	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—CD40LG—systemic scleroderma	0.000164	0.000734	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—CSK—systemic scleroderma	0.000162	0.000725	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—CD247—systemic scleroderma	0.000152	0.000682	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—HSPG2—systemic scleroderma	0.00014	0.000629	CbGpPWpGaD
Aminosalicylic Acid—ALOX5—Metabolism—NOS3—systemic scleroderma	0.000135	0.000602	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism—CTGF—systemic scleroderma	0.000134	0.0006	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—EDN1—systemic scleroderma	0.000107	0.00048	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—CTGF—systemic scleroderma	0.000106	0.000476	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—NOS3—systemic scleroderma	9.34e-05	0.000418	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—IL1B—systemic scleroderma	8.61e-05	0.000385	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—CCL2—systemic scleroderma	7.34e-05	0.000328	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—NOS3—systemic scleroderma	6.54e-05	0.000293	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—TGFB1—systemic scleroderma	6.17e-05	0.000276	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism—NOS3—systemic scleroderma	5.84e-05	0.000261	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—NOS3—systemic scleroderma	5.53e-05	0.000248	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—MMP9—systemic scleroderma	5.25e-05	0.000235	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—NOS3—systemic scleroderma	4.63e-05	0.000207	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—TGFB1—systemic scleroderma	4.32e-05	0.000194	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—TGFB1—systemic scleroderma	3.66e-05	0.000164	CbGpPWpGaD
